This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deffrasnes, C.
Right arrow Articles by Boivin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deffrasnes, C.
Right arrow Articles by Boivin, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2008, p. 279-287, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.00793-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus{triangledown}

Céline Deffrasnes,1 Marie-Ève Hamelin,1 Gregory A. Prince,2 and Guy Boivin1*

Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada,1 Virion Systems, Inc., Rockville, Maryland2

Received 19 June 2007/ Returned for modification 26 July 2007/ Accepted 22 October 2007

Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 µM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 x 104 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides.

* Corresponding author. Mailing address: CHUQ-CHUL, Room RC-709, 2705 Blvd Laurier, Quebec City, Quebec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: Guy.Boivin{at}crchul.ulaval.ca

{triangledown} Published ahead of print on 29 October 2007.

Antimicrobial Agents and Chemotherapy, January 2008, p. 279-287, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.00793-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Darniot, M., Pitoiset, C., Petrella, T., Aho, S., Pothier, P., Manoha, C. (2009). Age-Associated Aggravation of Clinical Disease after Primary Metapneumovirus Infection of BALB/c Mice. J. Virol. 83: 3323-3332 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»